Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Dec. 23, 2025 — Pfizer Inc. stock is ending 2025 in a familiar tug-of-war: a high-yield “value” profile on the one hand, and lingering uncertainty about the company’s post‑COVID growth engine on the other. Shares were trading around $25.15 on Tuesday, keeping the stock in the mid‑$20s range that’s defined much of its recent tape.

NYSE:PFE · Pfizer · Pharmaceuticals · Stock Market
Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk (NVO) Stock Jumps After FDA Approves Wegovy Pill: Today’s News, Analyst Forecasts, and 2026 Catalysts (23 December 2025)

Novo Nordisk A/S is back in the market’s spotlight on 23 December 2025 after a major regulatory milestone: the U.S. Food and Drug Administration approved a pill version of Wegovy, making it the first oral GLP‑1 receptor agonist cleared for chronic weight management in the U.S. The news sent Novo Nordisk shares sharply higher in early trading and reverberated across European markets, where the company’s move helped lift healthcare stocks. Novo Nordisk+2Reuters+2
23 December 2025
···
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Dec. 22, 2025 — After the closing bell, Alnylam Pharmaceuticals, Inc. is finishing the day in the spotlight for a reason that has nothing to do with a clinical readout—at least not directly. Monday marked the company’s first trading day as a Nasdaq-100 constituent, a mechanical event that can reshape near-term flows even when the underlying business story is unchanged.
23 December 2025
···
Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Stock (AMGN) News Today: Trump Drug‑Price Deals, Analyst Forecasts, and What to Watch Next — Dec. 22, 2025

Amgen Inc. is back in the spotlight on Monday, December 22, 2025, as investors weigh a wave of White House drug‑pricing agreements, a fast‑moving “most‑favored‑nation” pricing push, and what it could all mean for Amgen’s earnings power in 2026. The stock traded higher in Monday’s session, with market data showing shares around $331.
22 December 2025
··
AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Stock (ABBV) Before the Market Opens on Dec. 22, 2025: Drug-Pricing Talks, Dividend Signals, and the Next Catalysts

AbbVie Inc. heads into the Monday, December 22, 2025 U.S. market open with a familiar bull case—Skyrizi and Rinvoq continuing to replace lost Humira revenue—and a less familiar overhang: Washington’s accelerating push to reframe U.S. drug pricing through “most‑favored‑nation” style commitments and new direct-to-consumer programs.
22 December 2025
···
Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly (LLY) Stock: What to Know Before the U.S. Market Opens on Dec. 22, 2025

Eli Lilly and Company enters the final full holiday trading week of 2025 with momentum—and with headlines that can move the stock quickly in thin year‑end liquidity. The most important story remains Lilly’s dominance in obesity and diabetes medicines, but investors are now pricing in what comes next: oral GLP‑1 candidates, next‑generation “triple agonist” retatrutide, and a shifting U.S. policy backdrop that’s pushing drugmakers toward direct-to-consumer pricing and discount channels.
22 December 2025
··
AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

As of Sunday, December 21, 2025, AbbVie Inc. heads into a holiday-shortened trading week with shares hovering near the mid-$220s, after a high-volume rebound into Friday’s close. The setup for the week ahead is defined by two competing forces: strong underlying fundamentals and a renewed policy overhang as Washington accelerates its latest push to align U.S. drug prices with lower international benchmarks.
21 December 2025
··
Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

Johnson & Johnson (JNJ) Stock Week Ahead: Drug-Pricing Politics, Talc Verdicts, and Fresh FDA Wins Set the Tone (Dec 22–26, 2025)

As the market heads into a Christmas-shortened trading week, Johnson & Johnson is entering the final stretch of 2025 with an unusually headline-heavy mix of catalysts: U.S. drug-pricing negotiations tied to the White House, new talc-related jury verdicts, and a string of FDA and clinical updates that reinforce the company’s longer-term growth narrative.
21 December 2025
··
Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

Eli Lilly Stock Week Ahead (Dec. 22–26, 2025): LLY Enters Holiday Week With Obesity-Drug Catalysts, Pricing Headlines, and Policy Risk

As of Sunday, December 21, 2025, Eli Lilly and Company heads into a holiday-shortened trading week near recent highs, after a busy stretch of headlines spanning next-generation obesity drugs, potentially accelerated FDA review timelines, price cuts aimed at widening access, and a fast-evolving U.S. drug-pricing agenda.
21 December 2025
··
Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Stock (PFE) News Today: 2026 Guidance, Analyst Forecasts, Dividend Outlook, and Pipeline Catalysts (Updated Dec. 21, 2025)

Pfizer Inc. is heading into 2026 with a familiar mix of strengths and stress fractures: a fortress-scale commercial footprint and one of Big Pharma’s deepest development machines—paired with fading COVID-era revenue, looming loss-of-exclusivity headwinds, and heightened political pressure on U.S. drug pricing.
21 December 2025
··
AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

AbbVie Stock (ABBV) Outlook: Drug‑Pricing Deal Headlines, Fresh Analyst Targets, and the 2026 Catalysts Investors Are Watching

December 21, 2025 — AbbVie Inc. heads into the final stretch of 2025 near multi‑month highs, but the weekend news cycle has put a familiar theme back in the spotlight: U.S. drug pricing policy. At the same time, Wall Street’s newest notes show a market still split between strong fundamentals and policy/pipeline debates that could shape sentiment into 2026.
21 December 2025
··
Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

Amgen Stock (AMGN) News Today: TrumpRx Drug-Price Deal, FDA Approvals, Dividend Update, and 2026 Analyst Forecasts

December 20, 2025 — Amgen Inc. is closing out the year with a rare combination of near-term policy headlines and company-specific catalysts that matter to investors: a new U.S. drug-pricing deal tied to the TrumpRx rollout, fresh FDA approvals that expand the growth runway, reaffirmed shareholder returns via dividends, and a split—but active—Wall Street outlook heading into 2026.
20 December 2025
·
1 … 34 35 36 37 38 … 49
Follow on Google News
Add as preferred source Open in Google News